159 related articles for article (PubMed ID: 36502925)
1. Clinical and histopathologic characterization of SETD2-mutated colorectal cancer.
Bushara O; Wester JR; Jacobsen D; Sun L; Weinberg S; Gao J; Jennings LJ; Wang L; Lauberth SM; Yue F; Liao J; Yang GY
Hum Pathol; 2023 Jan; 131():9-16. PubMed ID: 36502925
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
Escobar D; Bushara O; Sun L; Liao J; Yang GY
Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
[TBL] [Abstract][Full Text] [Related]
3. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
[TBL] [Abstract][Full Text] [Related]
4. SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
Tsang JY; Lai ST; Ni YB; Shao Y; Poon IK; Kwan JS; Chow C; Shea KH; Tse GM
Breast Cancer Res Treat; 2021 Jun; 187(2):339-347. PubMed ID: 33844099
[TBL] [Abstract][Full Text] [Related]
5. The majority of β-catenin mutations in colorectal cancer is homozygous.
Arnold A; Tronser M; Sers C; Ahadova A; Endris V; Mamlouk S; Horst D; Möbs M; Bischoff P; Kloor M; Bläker H
BMC Cancer; 2020 Oct; 20(1):1038. PubMed ID: 33115416
[TBL] [Abstract][Full Text] [Related]
6. Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway.
Ma C; Liu M; Feng W; Rao H; Zhang W; Liu C; Xu Y; Wang Z; Teng Y; Yang X; Ni L; Xu J; Gao WQ; Lu B; Li L
Clin Transl Med; 2023 Nov; 13(11):e1475. PubMed ID: 37962020
[TBL] [Abstract][Full Text] [Related]
7. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
[TBL] [Abstract][Full Text] [Related]
8. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction.
Fang J; Huang Y; Mao G; Yang S; Rennert G; Gu L; Li H; Li GM
Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9598-9603. PubMed ID: 30181289
[TBL] [Abstract][Full Text] [Related]
9. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability.
Choi YJ; Oh HR; Choi MR; Gwak M; An CH; Chung YJ; Yoo NJ; Lee SH
Hum Pathol; 2014 Aug; 45(8):1674-81. PubMed ID: 24925220
[TBL] [Abstract][Full Text] [Related]
10. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.
Puccini A; Lenz HJ; Marshall JL; Arguello D; Raghavan D; Korn WM; Weinberg BA; Poorman K; Heeke AL; Philip PA; Shields AF; Goldberg RM; Salem ME
Oncologist; 2019 Mar; 24(3):319-326. PubMed ID: 30018131
[TBL] [Abstract][Full Text] [Related]
11. Histone Demethylase JMJD2D Interacts With β-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Peng K; Kou L; Yu L; Bai C; Li M; Mo P; Li W; Yu C
Gastroenterology; 2019 Mar; 156(4):1112-1126. PubMed ID: 30472235
[TBL] [Abstract][Full Text] [Related]
12. Unique clinicopathologic and genetic alteration features in early onset colorectal carcinoma compared with age-related colorectal carcinoma: a large cohort next generation sequence analysis.
Escobar D; Jones R; Gao J; Sun L; Liao J; Yang GY
Hum Pathol; 2020 Nov; 105():37-46. PubMed ID: 32916163
[TBL] [Abstract][Full Text] [Related]
13. Frequent activation of the β-catenin gene in sporadic colorectal carcinomas: A mutational & expression analysis.
Anwar M; Kochhar R; Singh R; Bhatia A; Vaiphei K; Mahmood A; Mahmood S
Mol Carcinog; 2016 Nov; 55(11):1627-1638. PubMed ID: 26373808
[TBL] [Abstract][Full Text] [Related]
14. SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.
Fahey CC; Davis IJ
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159833
[TBL] [Abstract][Full Text] [Related]
15. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
16. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive screening for mutations associated with colorectal cancer in unselected cases reveals penetrant and nonpenetrant mutations.
Kraus C; Rau TT; Lux P; Erlenbach-Wünsch K; Löhr S; Krumbiegel M; Thiel CT; Stöhr R; Agaimy A; Croner RS; Stürzl M; Hohenberger W; Hartmann A; Reis A
Int J Cancer; 2015 Mar; 136(6):E559-68. PubMed ID: 25142776
[TBL] [Abstract][Full Text] [Related]
19. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Martinelli G; Mancini M; De Benedittis C; Rondoni M; Papayannidis C; Manfrini M; Meggendorfer M; Calogero R; Guadagnuolo V; Fontana MC; Bavaro L; Padella A; Zago E; Pagano L; Zanotti R; Scaffidi L; Specchia G; Albano F; Merante S; Elena C; Savini P; Gangemi D; Tosi P; Ciceri F; Poletti G; Riccioni L; Morigi F; Delledonne M; Haferlach T; Cavo M; Valent P; Soverini S
Leukemia; 2018 Jan; 32(1):139-148. PubMed ID: 28663576
[TBL] [Abstract][Full Text] [Related]
20. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.
Kim IK; McCutcheon JN; Rao G; Liu SV; Pommier Y; Skrzypski M; Zhang YW; Giaccone G
Oncogene; 2019 Jan; 38(2):180-193. PubMed ID: 30093630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
